ERAL1 and breast cancer: In other words, we have not addressed the transcriptional response of breast cancer cells to estrogen or other ligands, as many other published studies reported [16, 26, 27, 38], but to the basal activity of ERα, which represents the leading protein of Luminal A and B subtypes.